1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014

Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Transitional Cell Cancer (Urothelial Cell Cancer). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Transitional Cell Cancer (Urothelial Cell Cancer) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Transitional Cell Cancer (Urothelial Cell Cancer) 26
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials 34
Prominent Drugs 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Eli Lilly and Company 37
Clinical Trial Overview of Eli Lilly and Company 37
F. Hoffmann-La Roche Ltd. 39
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 39
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
Bristol-Myers Squibb Company 41
Clinical Trial Overview of Bristol-Myers Squibb Company 41
Pfizer Inc. 42
Clinical Trial Overview of Pfizer Inc. 42
AstraZeneca PLC 43
Clinical Trial Overview of AstraZeneca PLC 43
Sanofi 44
Clinical Trial Overview of Sanofi 44
Laboratoires Pierre Fabre SA 45
Clinical Trial Overview of Laboratoires Pierre Fabre SA 45
Oncogenex Pharmaceuticals, Inc. 46
Clinical Trial Overview of Oncogenex Pharmaceuticals, Inc. 46
Amgen Inc. 47
Clinical Trial Overview of Amgen Inc. 47
Clinical Trial Overview of Top Institutes / Government 48
National Cancer Institute 48
Clinical Trial Overview of National Cancer Institute 48
Memorial Sloan Kettering Cancer Center 52
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 52
European Organization for Research and Treatment of Cancer 53
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 53
The University of Texas M. D. Anderson Cancer Center 54
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 54
University of Michigan 55
Clinical Trial Overview of University of Michigan 55
Southwest Oncology Group 56
Clinical Trial Overview of Southwest Oncology Group 56
The University of Chicago 57
Clinical Trial Overview of The University of Chicago 57
Fox Chase Cancer Center 58
Clinical Trial Overview of Fox Chase Cancer Center 58
Gynecologic Oncology Group 59
Clinical Trial Overview of Gynecologic Oncology Group 59
Five Key Clinical Profiles 60
Appendix 100
Abbreviations 100
Definitions 100
Research Methodology 101
Secondary Research 101
About GlobalData 102
Contact Us 102
Disclaimer 102
Source 103

List of Tables
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 27
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 37
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 39
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 41
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 42
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 43
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 44
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Laboratoires Pierre Fabre SA, 2014* 45
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncogenex Pharmaceuticals, Inc., 2014* 46
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 47
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 48
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 52
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 53
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 54
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 55
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 56
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 57
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014* 58
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gynecologic Oncology Group, 2014* 59

List of Figures
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 15
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 101

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US and South Korea

  • November 2016
    2 pages
  • Cancer  

  • United States  

    South Korea  

View report >

Related Market Segments :

Cancer
Clinical Trial
Therapy
Chemotherapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.